Details of the Drug

General Information of Drug (ID: DMDI6R4)

Drug Name
Dabigatran
Synonyms Pradaxa (TN)
Indication
Disease Entry ICD 11 Status REF
Stroke 8B20 Approved [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 471.5
Logarithm of the Partition Coefficient (xlogp) 1.7
Rotatable Bond Count (rotbonds) 9
Hydrogen Bond Donor Count (hbonddonor) 4
Hydrogen Bond Acceptor Count (hbondacc) 7
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [2]
Elimination
0% of drug is excreted from urine in the unchanged form [2]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 6.8271 micromolar/kg/day [3]
Water Solubility
The ability of drug to dissolve in water is measured as 1.8 mg/mL [2]
Chemical Identifiers
Formula
C25H25N7O3
IUPAC Name
3-[[2-[(4-carbamimidoylanilino)methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoic acid
Canonical SMILES
CN1C2=C(C=C(C=C2)C(=O)N(CCC(=O)O)C3=CC=CC=N3)N=C1CNC4=CC=C(C=C4)C(=N)N
InChI
InChI=1S/C25H25N7O3/c1-31-20-10-7-17(25(35)32(13-11-23(33)34)21-4-2-3-12-28-21)14-19(20)30-22(31)15-29-18-8-5-16(6-9-18)24(26)27/h2-10,12,14,29H,11,13,15H2,1H3,(H3,26,27)(H,33,34)
InChIKey
YBSJFWOBGCMAKL-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
216210
ChEBI ID
CHEBI:70752
CAS Number
211914-51-1
DrugBank ID
DB14726
TTD ID
D0M7JT
VARIDT ID
DR00241

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Coagulation factor IIa (F2) TT6L509 THRB_HUMAN Inhibitor [4]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [5]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Eyes absent homolog 1 (EYA1) OTHU807A EYA1_HUMAN Gene/Protein Processing [6]
Fibroblast growth factor 8 (FGF8) OTFU0IUW FGF8_HUMAN Gene/Protein Processing [6]
Forkhead box protein C2 (FOXC2) OT83P1E0 FOXC2_HUMAN Gene/Protein Processing [6]
Homeobox protein Hox-B9 (HOXB9) OTMVHQOU HXB9_HUMAN Gene/Protein Processing [6]
Homeobox protein MOX-1 (MEOX1) OTJEMT2D MEOX1_HUMAN Gene/Protein Processing [6]
Homeobox protein unc-4 homolog OTOW7WTS UNC4_HUMAN Gene/Protein Processing [6]
Neurogenin-2 (NEUROG2) OTAEMIGT NGN2_HUMAN Gene/Protein Processing [6]
Oligodendrocyte transcription factor 3 (OLIG3) OTU8XLAF OLIG3_HUMAN Gene/Protein Processing [6]
Paired box protein Pax-3 (PAX3) OTN5PJZV PAX3_HUMAN Gene/Protein Processing [6]
Paired box protein Pax-6 (PAX6) OTOC9876 PAX6_HUMAN Gene/Protein Processing [6]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Stroke
ICD Disease Classification 8B20
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
P-glycoprotein 1 (ABCB1) DTP P-GP 7.23E-01 -8.20E-02 -3.22E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6380).
2 BDDCS applied to over 900 drugs
3 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
4 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
5 Influence of ABCB11 and HNF4 genes on daclatasvir plasma concentration: preliminary pharmacogenetic data from the Kineti-C study. J Antimicrob Chemother. 2017 Oct 1;72(10):2846-2849.
6 Exposure-based assessment of chemical teratogenicity using morphogenetic aggregates of human embryonic stem cells. Reprod Toxicol. 2020 Jan;91:74-91. doi: 10.1016/j.reprotox.2019.10.004. Epub 2019 Nov 8.